Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Intra-Cellular Ther (ITCI)

Intra-Cellular Ther (ITCI)
127.08 +0.08 (+0.06%) 01/31/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 127.08 unch (unch) 01/31/25
Quote Overview for Fri, Jan 31st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
127.01
Day High
127.27
Open 127.27
Previous Close 127.00 127.00
Volume 1,786,700 1,786,700
Avg Vol 5,680,825 5,680,825
Stochastic %K 83.16% 83.16%
Weighted Alpha +88.10 +88.10
5-Day Change -0.27 (-0.21%) -0.27 (-0.21%)
52-Week Range 62.78 - 128.00 62.78 - 128.00
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,472,639
  • Shares Outstanding, K 106,017
  • Annual Sales, $ 464,370 K
  • Annual Income, $ -139,670 K
  • EBIT $ -122 M
  • EBITDA $ -129 M
  • 60-Month Beta 0.70
  • Price/Sales 20.88
  • Price/Cash Flow N/A
  • Price/Book 11.76

Options Overview Details

View History
  • Implied Volatility 13.06% ( +1.43%)
  • Historical Volatility 92.96%
  • IV Percentile 5%
  • IV Rank 4.19%
  • IV High 115.58% on 04/15/24
  • IV Low 8.57% on 01/17/25
  • Put/Call Vol Ratio 0.38
  • Today's Volume 1,548
  • Volume Avg (30-Day) 3,587
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 52,178
  • Open Int (30-Day) 21,934

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.05
  • Number of Estimates 7
  • High Estimate 0.22
  • Low Estimate -0.16
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +83.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
80.82 +57.23%
on 01/07/25
Period Open: 83.52
128.00 -0.72%
on 01/13/25
+43.56 (+52.16%)
since 12/31/24
3-Month
80.82 +57.23%
on 01/07/25
Period Open: 84.75
128.00 -0.72%
on 01/13/25
+42.33 (+49.95%)
since 10/31/24
52-Week
62.78 +102.42%
on 02/22/24
Period Open: 68.39
128.00 -0.72%
on 01/13/25
+58.69 (+85.82%)
since 01/30/24

Most Recent Stories

More News
How to Play J&J Stock After Q4 Beat & Soft 2025 Sales Guidance

Key TakeawaysJNJ beat Q4 earnings and sales estimates, with its Innovative Medicines Unit outperforming expectations.Sales in the unit rose 4.4% YOY to $14.33 billion, led by key drugs such as Darzalex,...

ITCI : 127.08 (+0.06%)
JNJ : 152.15 (-0.47%)
KVUE : 21.29 (-1.98%)
AMGN : 285.42 (+0.49%)
J&J's Q4 Earnings Beat, Stock Down on Tepid 2025 Sales Guidance

Johnson & Johnson’s JNJ fourth-quarter 2024 earnings came in at $2.04 per share, which beat the Zacks Consensus Estimate of $2.00. Earnings declined 10.9% from the year-ago period. Adjusted earnings...

ITCI : 127.08 (+0.06%)
JNJ : 152.15 (-0.47%)
KVUE : 21.29 (-1.98%)
AMGN : 285.42 (+0.49%)
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Earnings?

Key TakeawaysThe Zacks Consensus Estimate for JNJ Q4 sales and earnings is $22.5 billion and $2.01 per share, respectively.JNJ's performance has impressed, as the company exceeded earnings expectations...

ITCI : 127.08 (+0.06%)
JNJ : 152.15 (-0.47%)
KVUE : 21.29 (-1.98%)
AMGN : 285.42 (+0.49%)
MarketBeat Week in Review – 01/13 - 01/17

The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally

TGT : 137.91 (-1.80%)
NVDA : 120.07 (-3.67%)
SNOW : 181.51 (+1.24%)
F : 10.08 (-0.79%)
JPM : 267.30 (-0.35%)
JNJ : 152.15 (-0.47%)
NKE : 76.90 (-1.83%)
RGTI : 13.17 (+7.07%)
GS : 640.40 (-0.82%)
MCD : 288.70 (-0.56%)
LCID : 2.76 (+1.47%)
SOUN : 14.15 (+1.07%)
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?

JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive

ITCI : 127.08 (+0.06%)
JNJ : 152.15 (-0.47%)
The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK and Intra-Cellular

For Immediate ReleaseChicago, IL – January 15, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

ITCI : 127.08 (+0.06%)
JNJ : 152.15 (-0.47%)
LLY : 811.08 (-1.48%)
GSK : 35.27 (-0.25%)
Stock market today: Wall Street mostly rises after encouraging inflation data despite Lilly's drag

Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks kept indexes in check

META : 689.18 (+0.32%)
NVDA : 120.07 (-3.67%)
AAPL : 236.00 (-0.67%)
C : 81.43 (-0.53%)
$SPX : 6,040.53 (-0.50%)
JPM : 267.30 (-0.35%)
JNJ : 152.15 (-0.47%)
HEES : 88.69 (+0.02%)
M : 15.58 (-1.20%)
$IUXX : 21,478.05 (-0.14%)
URI : 758.06 (-2.07%)
SIG : 59.23 (-1.82%)
JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference

The JP Morgan Healthcare Conference, which is being held in San Francisco this year, has been much more active than last year. Among some of the top news at the conference were M&A deal announcements by...

ITCI : 127.08 (+0.06%)
JNJ : 152.15 (-0.47%)
LLY : 811.08 (-1.48%)
GSK : 35.27 (-0.25%)
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer

Intra-Cellular Therapies ITCI signed a definitive agreement with pharma bigwig Johnson & Johnson JNJ. Per the terms, the pharma giant will acquire all outstanding shares of ITCI for $132 per share in cash,...

ITCI : 127.08 (+0.06%)
SDZNY : 47.7700 (+0.03%)
JNJ : 152.15 (-0.47%)
Stock Index Futures Climb on Trump Tariffs Report, U.S. PPI Data and Fed Speak in Focus

March S&P 500 E-Mini futures (ESH25) are up +0.49%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.67% this morning as a report indicating the U.S. might take a gradual approach to hiking tariffs...

CVS : 56.48 (-0.60%)
HUM : 293.23 (-1.24%)
NVDA : 120.07 (-3.67%)
AAPL : 236.00 (-0.67%)
JD-.LN : 89.120 (+2.23%)
HEES : 88.69 (+0.02%)
ESH25 : 5,963.00 (-1.72%)
MOS : 27.89 (-2.41%)
KBH : 67.10 (-2.41%)
AEHR : 11.33 (-0.09%)
ITCI : 127.08 (+0.06%)
V : 341.80 (-0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular...

See More

Key Turning Points

3rd Resistance Point 127.49
2nd Resistance Point 127.38
1st Resistance Point 127.23
Last Price 127.08
1st Support Level 126.97
2nd Support Level 126.86
3rd Support Level 126.71

See More

52-Week High 128.00
Last Price 127.08
Fibonacci 61.8% 103.09
Fibonacci 50% 95.39
Fibonacci 38.2% 87.69
52-Week Low 62.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Exclusive Barchart Webinar: Unlock the Power of High-Accuracy Option Trading